ALB and COVID-19: Finally, the present investigation suggests that restoring abnormal S1P levels to a normal range, and balancing its binding to albumin and apoM to healthy conditions, may have the potential to be a therapeutic target for reducing the risk of disease progression and death, and, not last, to mount an effective immune response after vaccination in patients with COVID‐19.